Ortiz Romero, Pablo Luis
Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review. [revisión] - Actas dermo-sifiliográficas, 2014 - 105(5):438-45.
Formato Vancouver:
Fernández Guarino M, Ortiz Romero PL, Fernández-Misa R, Montalbán C. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review. Actas Dermosifiliogr. 2014 Jun;105(5):438-45.
PMID: 23540593
Contiene 52 referencias
Rituximab is a chimeric mouse-human antibody that targets the CD20 antigen, which is found in both normal and neoplastic B cells. In recent years, it has been increasingly used to treat cutaneous B-cell lymphoma and is now considered an alternative to classic treatment (radiotherapy and surgery) of 2 types of indolent lymphoma, namely, primary cutaneous follicle center lymphoma and primary cutaneous marginal zone B-cell lymphoma. Rituximab is also administered as an alternative to polychemotherapy in the treatment of primary cutaneous large B-cell lymphoma, leg type. Its use as an alternative drug led to it being administered intralesionally, with beneficial effects. In the present article, we review the literature published on the use of rituximab to treat primary cutaneous B-cell lymphoma.
Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review. [revisión] - Actas dermo-sifiliográficas, 2014 - 105(5):438-45.
Formato Vancouver:
Fernández Guarino M, Ortiz Romero PL, Fernández-Misa R, Montalbán C. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review. Actas Dermosifiliogr. 2014 Jun;105(5):438-45.
PMID: 23540593
Contiene 52 referencias
Rituximab is a chimeric mouse-human antibody that targets the CD20 antigen, which is found in both normal and neoplastic B cells. In recent years, it has been increasingly used to treat cutaneous B-cell lymphoma and is now considered an alternative to classic treatment (radiotherapy and surgery) of 2 types of indolent lymphoma, namely, primary cutaneous follicle center lymphoma and primary cutaneous marginal zone B-cell lymphoma. Rituximab is also administered as an alternative to polychemotherapy in the treatment of primary cutaneous large B-cell lymphoma, leg type. Its use as an alternative drug led to it being administered intralesionally, with beneficial effects. In the present article, we review the literature published on the use of rituximab to treat primary cutaneous B-cell lymphoma.
